Page last updated: 2024-11-03

rabeprazole and Diarrhea

rabeprazole has been researched along with Diarrhea in 3 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.

Research Excerpts

ExcerptRelevanceReference
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)."9.17Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013)
"The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD)."5.19Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. ( Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014)
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)."5.17Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013)
"Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects."2.70Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haddad, I2
Kierkus, J2
Tron, E2
Ulmer, A2
Hu, P2
Sloan, S2
Silber, S2
Leitz, G1
Leitz, GJ1
Wong, BC1
Wong, WM1
Yee, YK1
Hung, WK1
Yip, AW1
Szeto, ML1
Li, KF1
Lau, P1
Fung, FM1
Tong, TS1
Lai, KC1
Hu, WH1
Yuen, MF1
Hui, CK1
Lam, SK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891]Phase 3127 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg0.2
Rabeprazole Sodium 1.0 mg/kg0.2

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-1.3
Rabeprazole Sodium 1.0 mg/kg-1.0

The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-2.9
Rabeprazole Sodium 1.0 mg/kg-1.4

The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-11.5
Rabeprazole Sodium 1.0 mg/kg-8.5

The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks

InterventionPercentage of participants (Number)
Rabeprazole Sodium 0.5 mg/kg78
Rabeprazole Sodium 1.0 mg/kg83

The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks

InterventionPercentage of patients (Number)
Rabeprazole Sodium 0.5 mg/kg92
Rabeprazole Sodium 1.0 mg/kg88

Trials

3 trials available for rabeprazole and Diarrhea

ArticleYear
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:6

    Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es

2013
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
    Journal of pediatric gastroenterology and nutrition, 2014, Volume: 58, Issue:4

    Topics: Abdominal Pain; Child; Child, Preschool; Diarrhea; Double-Blind Method; Endoscopy, Gastrointestinal;

2014
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid

2001